Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2008

View Archived Issues

Novel contraceptive agents disclosed in recent Wyeth patents

High affinity ligands for CLC-K channels discovered

Recombinant human plasma protease C1 inhibitor safe, beneficial in hereditary angioedema

Final EDEMA3 data show efficacy of DX-88 in hereditary angioedema

Multiple effects of KP-496 observed in guinea pig asthma model

Sustained rilonacept effects seen in cryopyrin-associated periodic syndromes

Novel Fc receptor peptide antagonist effectively reduces IgG levels in monkeys

PhytoMedical to initiate third phase of drug development program for novel anticancer compounds

Alimera and pSivida amend license and collaboration agreement for Medidur FA

Centocor and Schering-Plough have submitted a Marketing Authorization Application to the EMEA

TorreyPines initiates phase II NGX-267 study for treatment of xerostomia

Cytopia selects JAK2 clinical candidate for myeloproliferative disorders

FDA places clinical hold on investigational vaccine Heplisav

Mapreg's MAP-4343 granted orphan status in Europe for spinal cord injury

QLT reports positive FDA action on Aczone sNDA

Takeda submits NDA for a fixed-dose combination tablet of Blopress with diuretic in Japan

NPS reports positive top-line results for Gattex extension study

BioNumerik and ASKA present results from phase III Tavocept trial

Ardea Biosciences presents positive phase IIa results for RDEA-806 in HIV

Recent Kowa patent describes new treatment options for diabetic nephropathy

Merck Serono launches Cyanokit for cyanide poisoning in Japan

FDA designates priority review for Gardasil sBLA for women 27 through 45 years of age

Arpida submits NDA for intravenous iclaprim for complicated skin infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...